ISSN: 3139-3683

JOURNAL OF HEALTH SYNAPSE (JHS)
Peer Reviewed Refereed Open Access International Multidisciplinary Journal

Publisher: Scientistic Era Private Limited
Journal Hompage: https://healthsynapse.org

Nanoengineered Drug Delivery Systems to Overcome Multidrug Resistance in Cancer

Aakash Singh Panwar[a]*, Abhimanyu Singh Rathore[a] Kiran kaithwar[a] Anuradha Dhokpande[a]

[a]*SAGE University, Department of Pharmaceutical science, Kailod Kartal, Indore-Dewas By-Pass, Road, Indore, Madhya Pradesh 452020*

This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author(s) and the source are properly cited.

ARTICLE INFO

KEYWORDS:
Multidrug resistance; P-glycoprotein; Nanomedicine; Stimuli-responsive nanoparticles; siRNA co-delivery; Tumor microenvironment; Cancer drug delivery; Endocytosis bypass; Translational nanotechnology.

ARTICLE HISTORY
Received Date: 15 April 2026
Revised Date: 28April 2026
Accepted Date: 29 May 2026
Published Date: 30 June 2026

CITATION
Panwar, A. S., 2026 Nanoengineered Drug Delivery Systems to Overcome Multidrug Resistance in Cancer. *Journal of Health Synapse (JHS), 1(2), 65-74.*
https://doi.org/10.67529/jhs.v1i2.7

A B S T R A C T

Multidrug resistance (MDR) remains one of the most critical barriers to successful cancer chemotherapy, causing relapse, metastasis, and treatment failure. MDR arises through a network of mechanisms including drug efflux transporter overexpression (e.g., P-glycoprotein/ABCB1, BCRP/ABCG2, MRPs), apoptosis evasion, enhanced DNA repair, tumor hypoxia, metabolic reprogramming, and cancer stem cell (CSC) survival. Conventional attempts to reverse MDR using efflux pump inhibitors have largely failed clinically due to systemic toxicity and pharmacokinetic drug–drug interactions. Nanoengineered drug delivery systems offer a transformative solution by altering biodistribution, improving intracellular drug accumulation, bypassing membrane efflux via endocytosis, enabling stimuli-responsive release, and supporting co-delivery of chemosensitizers, gene regulators (siRNA/shRNA), or immunomodulators.

Advanced nanocarriers—including liposomes, solid lipid nanoparticles, polymeric nanoparticles, micelles, dendrimers, mesoporous silica, gold nanoparticles, and hybrid biomimetic systems—can be tuned by nanoengineering to control size, surface charge, stealth behavior, and ligand-directed targeting. Additionally, tumor microenvironment (TME) features such as acidic pH, high glutathione (GSH), hypoxia, enzyme overexpression, and abnormal vasculature can be exploited for precision release, thereby improving therapeutic index while reducing systemic toxicity. Case studies demonstrate that nano-enabled co-delivery strategies (e.g., doxorubicin + MDR1/P-gp siRNA; paclitaxel + chemosensitizers) significantly resensitize resistant tumors in preclinical models. However, clinical translation remains challenged by immunogenicity, rapid clearance, scale-up constraints, batch reproducibility, regulatory complexity, and limited patient stratification for EPR variability.

This review critically analyzes MDR biology, nanoengineering frontiers, and clinically relevant design principles, and provides a roadmap for bench-to-bedside translation. Future success will depend on scalable manufacturing, strong safety evaluation, biomarker-driven patient selection, and rational combination therapies aligned with cancer resistance biology.

I. Introduction

The Urgency of Overcoming Multidrug Resistance

Cancer chemotherapy fails in many patients not because drugs are weak, but because tumor cells become adaptive systems capable of resisting multiple unrelated drugs [1-4]. MDR is especially common in aggressive cancers such as triple-negative breast cancer, ovarian cancer, pancreatic cancer, hepatocellular carcinoma, lung cancer, leukemia, and metastatic tumors. The hallmark of MDR is that after exposure to one drug, cancer cells may develop cross-resistance to several drugs with different mechanisms [5-8].

Historically, MDR was linked strongly to efflux pumps (especially P-gp), which actively export anticancer drugs out of cells, decreasing intracellular drug concentration [9-12]. Unfortunately, direct MDR inhibitors (1st–3rd generation efflux blockers) failed due to toxicity, low

selectivity, and unpredictable drug interactions. Modern nanomedicine therefore offers a more physiological strategy: instead of blocking pumps everywhere in the body, deliver the drug in a way that cancer cells cannot reject it.

Nanoengineered delivery systems improve chemotherapy outcomes by:

- Increasing tumor accumulation (passive/active targeting)
- Enabling endocytosis-mediated uptake (bypassing pumps)
- Delivering two or more agents with synchronized release
- Exploiting TME triggers (pH, redox, enzymes, hypoxia) for on-site activation
- Reducing systemic toxicity by controlled release and biodistribution design

Clinical progress in nanomedicine has accelerated with approved products such as liposomal and albumin-bound formulations, and a newer wave of stimuli-responsive and combination systems reaching trials [13-16].

2. The Biology of Multidrug Resistance in Cancer

MDR is multifactorial, involving genetic, epigenetic, biochemical, and microenvironmental changes. It can be:

- Intrinsic MDR: present before treatment (tumor heterogeneity)
- Acquired MDR: develops after repeated drug exposure

2.1 Core Molecular Mechanisms

(A) Drug efflux transporters

ABC transporters pump drugs out using ATP:

- P-gp (ABCB1/MDR1)
- MRP1 (ABCC1)
- BCRP (ABCG2)

These transporters lower intracellular drug concentration → reduced cytotoxicity.

(B) Drug target alteration

Mutations or downregulation of target proteins reduce drug binding [17].

(C) Enhanced DNA repair

Cancer cells increase repair after chemotherapy-induced DNA damage [18].

(D) Apoptosis evasion

p53 defects, Bcl-2 upregulation, survival signaling (PI3K/Akt, NF-κB) [19].

(E) Tumor microenvironment (TME) resistance

Hypoxia and acidic environment reduce drug effect and promote survival pathways [20].

(F) Cancer stem cells (CSCs) & EMT

CSCs survive therapy, regenerate tumor, show high efflux and strong repair capacity [21].

Table 1: Major MDR Mechanisms and Nano-Intervention Opportunities

MDR mechanism	Key features	Result	Nano-strategy to overcome
ABC efflux pumps (P-gp, BCRP, MRP)	Active drug export	Low intracellular drug	Endocytosis uptake, pump-silencing siRNA, co-delivery of inhibitors
Apoptosis resistance	p53 mutation, Bcl-2 ↑	Cell survival	Co-delivery of pro-apoptotic drugs, mitochondria targeting
DNA repair ↑	Repair enzymes ↑	Drug resistance	Nuclear delivery, DNA damage amplification, ROS therapy
TME hypoxia & acidity	HIF-1α ↑, low pH	Reduced drug response	pH/hypoxia-triggered release, oxygen generators
CSC survival & EMT	Stemness, metastasis	Relapse	Targeting CSC markers, combination chemo + gene therapy
Drug metabolism/detox	CYP changes, glutathione pathways	Drug inactivation	Redox-triggered release, metabolic inhibitors

(Adapted conceptually from MDR biology and nanomedicine strategies)



Fig. 1: Biology of Multidrug Resistance (MDR) in Cancer

3. Nanoengineering Frontiers: Designing Versatile Delivery Platforms

Nanoengineering means designing NPs with controlled size, surface chemistry, drug loading, targeting, and release behavior, to defeat MDR at multiple barriers [22].

The "best" nanocarrier is not universal; it must match:

- drug physicochemical properties
- tumor type and resistance mechanism
- delivery route (IV/oral/local)
- required release profile (fast vs sustained)

3.1 Nanocarriers: Lipid-Based, Polymer-Based, and Inorganic Systems

3.1.1 Lipid-based systems

Liposomes, SLNs, NLCs provide high biocompatibility and easy encapsulation [23-25].

Advantages

- biocompatible
- good for hydrophobic + hydrophilic drugs
- clinically proven platform (liposomes)

Limitations

- stability issues in plasma
- leakage in storage unless optimized

Lipid-based strategies are widely explored for resistant tumors due to biocompatibility and modifiable surfaces [26-28].

3.1.2 Polymeric systems

Includes PLGA NPs, PEG-PLA, micelles, dendrimers, nanogels [29].

Advantages

- controlled release capability
- high structural stability
- stimulus-responsive linkers possible

Limitations

- polymer toxicity depends on chemistry
- batch consistency issues

3.1.3 Inorganic and hybrid nanosystems

Includes:

- mesoporous silica nanoparticles (MSNs)
- gold nanoparticles
- magnetic iron oxide NPs
- carbon dots / quantum dots (theranostics)

These can offer imaging + therapy, high loading, and triggered release. Classic evidence exists for MSNs co-delivering doxorubicin + siRNA to overcome resistance [30].

Table 2: Nanocarrier Classes and MDR-Reversal Strengths

Platform	Examples	Best MDR advantage	Major limitation
Liposomes	PEGylated liposomes	Clinically validated, reduced toxicity	Stability, leakage
SLN/NLC	lipid matrix carriers	High uptake, scalable	limited loading for hydrophilic drugs
Polymeric NPs	PLGA, PEG-PLA	sustained release, tunable	scale-up + reproducibility
Micelles	polymeric micelles	solubilize hydrophobic drugs	dilution instability
Dendrimers	PAMAM-based	high functionalization	potential toxicity

Platform	Examples	Best MDR advantage	Major limitation
MSNs	mesoporous silica	high loading + sequential release	clearance concerns
Gold/magnetic	inorganic cores	imaging + triggered delivery	long-term safety



Fig. 2: Nanoengineering Toolbox to Reverse MDR

3.2 Targeting Strategies: Active Targeting, Passive Targeting, and Stimuli Responsiveness

3.2.1 Passive targeting (EPR effect)

Nanoparticles (typically 30–150 nm) can accumulate in tumors due to leaky vasculature and poor lymphatic drainage (EPR). This is the base principle behind many clinical nanomedicines [31-32].

Reality: EPR differs widely between patients → one reason clinical results vary.

3.2.2 Active targeting

Active targeting = adding ligands to bind tumor receptors:

- folate receptor (folic acid)
- transferrin receptor
- EGFR/HER2 antibodies
- peptides (RGD-integrin binding)

Active targeting improves internalization via receptor-mediated endocytosis, aiding MDR bypass [33-35].

3.2.3 Stimuli-responsive targeting

Stimuli can be:

Internal triggers

- acidic pH (tumor/endosome)
- high GSH (redox)
- enzymes (MMPs, cathepsins)
- hypoxia

External triggers

- light (photo-triggered release)
- ultrasound
- magnetic field

Stimuli-responsive nanocarriers have strong potential for MDR reversal by localized activation and reduced off-target toxicity [36-38].

Table 3: Stimuli-Responsive Nano-Design for MDR Cancer

Stimulus	Tumor feature	Smart design	MDR benefit
pH-triggered	acidic TME/endosomes	hydrazone linkers, pH-sensitive shells	intracellular burst release
Redox-triggered	high GSH in tumor cells	disulfide bonds	releases drug inside resistant cells
Enzyme-triggered	MMP/cathepsins ↑	enzyme-cleavable peptides	selective activation
Hypoxia-triggered	low oxygen	hypoxia-activated prodrugs	works in resistant hypoxic zones
Light-triggered	external control	photo-cleavable gates	sequential release strategies

3.3 Controlled Release and Pharmacokinetics Optimization

A key nanoengineering victory is not only "delivering more drug", but delivering it at the right time [39-42].

Important parameters:

- Drug release kinetics: burst vs sustained
- Circulation time: PEGylation increases half-life but may reduce uptake
- Size & charge: influences tumor penetration and immune clearance
- Protein corona formation: changes targeting outcomes

New clinical nanomedicines emphasize combination therapy, active targeting, and stimuli-responsiveness for real therapeutic gains [43-46].

4. Overcoming Drug Efflux and Cellular Barriers with Nanotechnology

4.1 Bypassing Efflux Pumps via Endocytosis

This is the strongest nano-logic against MDR:

Free drug → enters via diffusion → efflux pumps expel it

Nano-drug → enters via endocytosis → avoids immediate efflux

Once inside, drug release occurs near cytosol/organelles and can overwhelm resistance [47-50].

Co-delivery approach is highly effective:

- chemo drug + P-gp siRNA/shRNA
- chemo drug + chemosensitizer

Non-viral co-delivery systems (siRNA + chemotherapy) are now among the most promising MDR reversal strategies [51-52].



Fig. 2: How Nanoparticles Bypass Efflux Pumps

4.2 Tumor Microenvironment Modulation to Enhance Delivery

4.2.1 Barriers

- dense extracellular matrix (ECM)
- high interstitial fluid pressure (IFP)
- abnormal vasculature
- immune suppression (M2 macrophages)

4.2.2 Nano-solutions

- ECM-degrading enzymes (hyaluronidase strategies)
- oxygen modulation systems for hypoxia
- macrophage reprogramming systems
- charge-switching nanoparticles (neutral in blood → positive in tumor)

Resistance and tumor heterogeneity are central reasons why MDR persists and why multifunctional nano-systems are preferred [53].

4.3 Nuclear and Intracellular Targeting for Maximum Efficacy

Many anticancer drugs act on DNA or nuclear targets (doxorubicin, cisplatin, etc.). MDR can block nuclear accumulation [54-55].

Nanoengineering routes

- Endosomal escape peptides (proton sponge effect)
- Nuclear localization signals (NLS peptides)

Organelle targeting:

- mitochondria targeting (triphenylphosphonium, TPP)
- lysosome-targeted prodrugs

Sequential and timed co-delivery is important: gene silencing first (P-gp ↓), then chemo release [56].

5. Safety, Biocompatibility, and Translational Challenges

5.1 Immunogenicity and Clearance Pathways

Even effective nanoparticles can fail clinically because of:

- opsonization (protein corona)
- uptake by liver/spleen macrophages (MPS clearance)
- complement activation (infusion reactions)
- accelerated blood clearance after repeated dosing (anti-PEG)

Nanomedicine–immune interactions are now considered a primary translation bottleneck [57].

5.2 Scalability, Manufacturing Standards, and Regulatory Considerations

To enter clinical use, nanomedicines require:

- reproducible particle size & PDI
- stable zeta potential profiles
- validated loading/encapsulation efficiency

- release testing under physiologic conditions
- GMP-compliant batch manufacturing
- long-term stability data

Clinical translation analysis highlights that successful products have strong manufacturability and clear clinical benefit over standard formulations.

5.3 Long-Term Safety and Monitoring in Clinical Settings

Long-term concerns:

- inorganic NP accumulation in organs
- chronic immune effects
- off-target gene silencing (siRNA systems)
- unexpected biodistribution in humans vs mice

Therefore, regulatory agencies require robust safety profiling and post-marketing surveillance strategies [58].

6. Case Studies: Promising Nanoengineered Solutions in Preclinical and Early Clinical Phases

6.1 FDA/Clinically Established Nanomedicines Relevant to MDR

Even though not designed specifically for MDR reversal, many approved nanomedicines contribute by:

- improving tumor drug exposure
- reducing toxicity → allowing higher effective dosing
- improving tolerability for combination regimens

Examples:

- Doxil® (PEGylated liposomal doxorubicin)
- Abraxane® (albumin-bound paclitaxel nanoparticles)
- Onivyde® (liposomal irinotecan)
- Vyxeos® (liposomal daunorubicin + cytarabine)

These approvals are milestones proving nanomedicine clinical feasibility [59].

Table 4: Clinically Used Nanomedicines (Examples) and MDR-Relevance

Product	Type	Drug	Key clinical advantage	MDR relevance
Doxil®	PEG-liposome	Doxorubicin	reduces cardiotoxicity	increases tumor exposure, can overwhelm efflux
Abraxane®	albumin NP	Paclitaxel	improved delivery vs Cremophor	improves uptake & penetration
Onivyde®	liposome	Irinotecan	prolonged circulation	more drug at tumor site
Vyxeos®	liposome combo	Dauno + Ara-C	fixed drug ratio synergy	maintains synergistic ratio

(Clinical nanomedicine landscape reviewed extensively)

6.2 Co-delivery of siRNA + Chemotherapy (Strongest MDR-Specific Strategy)

A modern high-impact strategy is to deliver:

- Chemotherapy (kills tumor)
- siRNA/shRNA against MDR pathways (P-gp/MDR1, anti-apoptosis genes)

Non-viral vector co-delivery systems have rapidly progressed because siRNA alone is unstable and weak clinically, but becomes powerful when combined in one nanoparticle.

6.3 Mesoporous Silica Nanoparticles (MSNs) for Drug + Gene Co-Delivery

A landmark approach demonstrated co-delivery of doxorubicin + siRNA using multifunctional MSNs to resensitize MDR cells [60].

Why MSNs are useful

- high drug loading
- gated release designs possible
- sequential release potential

6.4 Stimuli-responsive sequential release systems

Sequential release = gene silencing first → chemotherapy next.

Light-triggered sequential release strategies have shown improved MDR reversal by controlling timing [61].

7. Strategic Roadmap: From Lab Bench to Patient Benefit



Fig. 4: Bench-to-bedside Roadmap

To convert nano-MDR research into clinical reality, follow a stage-wise pipeline:

Stage 1: Resistance biology mapping

- Identify the dominant MDR mechanism (efflux vs apoptosis vs hypoxia etc.)

Stage 2: Rational nanocarrier selection

- choose lipid/polymer/inorganic based on drug and tumor needs

Stage 3: Quality-by-design nanoengineering

- optimize size, charge, loading, release, stability, targeting ligand density

Stage 4: Predictive in-vitro models

- 2D MDR cell lines (e.g., MCF-7/ADR)
- 3D tumor spheroids
- tumor-on-chip platforms

Stage 5: In-vivo validation

- orthotopic MDR xenografts
- biodistribution studies
- immunotoxicity assessment

Stage 6: Translation readiness

- GMP manufacturability
- batch reproducibility
- stability at storage conditions
- regulatory documentation

Clinical translation frameworks emphasize that successful nanomedicines solve manufacturability + clinical benefit simultaneously [62].

8. Conclusion

Nanoengineered drug delivery systems provide a highly rational and clinically realistic path to overcome multidrug resistance in cancer. By bypassing membrane efflux pumps through endocytosis, co-delivering chemosensitizers or gene silencers, and exploiting tumor microenvironment triggers for controlled release, nanomedicine directly targets the biological roots of resistance rather than relying on systemic MDR inhibitors. The most promising direction is multifunctional combination nanotherapy—particularly chemo-siRNA co-delivery platforms—because MDR is not a single-gene problem but a network phenotype. Nonetheless, translation remains limited by immune clearance, safety concerns, and manufacturing barriers. Future clinical success will depend on standardized GMP scale-up, strong long-term safety monitoring, and biomarker-guided patient selection to address EPR variability and tumor heterogeneity. With these strategies, nanoengineered therapeutics can shift MDR cancer therapy from “dose escalation” to precision resensitization, improving survival and reducing toxicity.

References:

1. Sun Q, Zhou Z, Qiu N, Shen Y. Rational design of cancer nanomedicine: nanoproperty integration and synchronization. *Adv Mater.* 2017;29(14):1606628.
2. Zhang Y, Wang Y, Chen Y, et al. Overcoming multidrug resistance by nanoparticle-based drug delivery systems. *Drug Discov Today.* 2020;25(9):1746–1758.
3. Conde J, Oliva N, Zhang Y, Artzi N. Local triple-combination therapy results in tumour regression and prevents recurrence in a colon cancer model. *Nat Mater.* 2016;15(3):353–363.
4. Torchilin VP. Multifunctional nanocarriers. *Adv Drug Deliv Rev.* 2012;64:302–315.
5. Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers. *Nat Biotechnol.* 2015;33(9):941–951.
6. Gandhi MY, Prasad SB, Kumar V, Soni H, Rawat H, Mishra SK, Grewal J, Singh S, Charde V, Gupta A, Jha SK. Quantification of phytochemicals and metal ions as well as the determination of volatile compounds, antioxidant, antimicrobial and antacid activities of the Mimosa pudica L. leaf: Exploration

of neglected and under-utilized part. Chemistry & biodiversity. 2023 Oct;20(10):e202301049.
7. Shamim, Ali S, Ali T, Sharma H, Kishor BN, Jha SK. Recent advances in monodisperse gold nanoparticle delivery, synthesis, and emerging applications in cancer therapy. Plasmonics. 2025 Sep;20(9):7121-41.
8. Gandhi Y, Kumar V, Singh G, Prasad SB, Mishra SK, Soni H, Rawat H, Singh S, Charde V, Gupta A, Dhanjal DS. Chemoprofiling and medicinal potential of underutilized leaves of Cyperus scariosus. Scientific Reports. 2024 Mar 27;14(1):7263.
9. Jha SK, Islam M, Kumar R, Rana L, Saifi MA, Ali S, Alam N. Evaluation of Vernonia amygdalina del. containing phyto constituents a medicinal plant compound as new potential inhibitors of Monkey pox virus using molecular docking analysis. World J Adv Res Rev. 2023;17(1):1112-22.
10. Singh A, Jha SK, Dwivedi PC, Srivastava U, Pal A. Revolutionizing healthcare: Integrating electronics, AI, traditional, and conventional methods. World J Adv Res Rev. 2024;23:2426-34.
11. Lohiya GV. Conjunctivitis in unusual populations: A review of rare cases and challenges in diagnosis and management. World Journal of Advanced Research and Reviews. 2023 Sep 29.
12. Lohiya GV. Conjunctivitis in unusual populations: A review of rare cases and challenges in diagnosis and management. World Journal of Advanced Research and Reviews. 2023 Sep 29.
13. Doshi R, Lohiya G. Synthesis, in-silico design and spectral characterization, elucidation of Cannabis sativa L. cannabaceae containing phytoconstitutents demonstrating novel therapeutic efficacy against epilepsy.
14. Jha SK, Mishra AK, Kumar V, Dane G, Kumari S, Charde V, Saddam M, Jagtap C, Chuhan S, Chaturvedi SK, Narasimhaji CV. Ecological and Behavioral Impacts of COVID-19 on Human Existence and potential preventive measures through traditional and alternative medicine–A Narrative review. Pharmacological Research-Natural Products. 2024 Jun 1;3:100042.
15. Sonkar V, Jha SK, Tiwari S, Akarsh A, Priya S, Sharan P, Sharan A. Characterization and explanation of the soil fertility state of Sakaldiha block in the Chandauli District of Uttar Pradesh's industrial area. World J Adv Res Rev. 2023;18:063-72.
16. Singh NK, Sengar AS, Jha SK. A review of Ayurvedic measures for preventing COVID-19 and promoting health during pregnancy. Journal of Indian System of Medicine. 2024 Apr 1;12(2):61-5.
17. Chauhan S, Jha SK, Tamta A, Sharma V, Kumar C, Lohiya G, Gadgul A, Satpute K, Chalmale N, Chauhan P, Chaturvedi SK. Descriptive analytical study based on profiling, morphological, pomological and pharmacological traits to identify the genotypes of the promising mango Mangifera indica L. World J Adv Res Rev. 2023;19:1544-53.
18. Khan R, Maheshwari D, Chauhan S, Lohiya GV, Kumar C, Antil I, Sharma S, Garg Y, Chauhan P, Jha SK. Exploring the potential therapeutic value of Solanum lycopersicum L. phytoconstituents for Parkinson's disease through molecular docking analysis. World J Adv Res Rev. 2023;20:488-501.
19. Jha SK, Singh N, Shanker OR, Antil I, Baghel JS, Huddar V, Tripathi R. A review on integrative approaches in oncology: bridging ayurvedic medicine and modern cancer therapeutics. Frontiers in Natural Products. 2025 Aug 22;4:1635197.
20. Tamta A, Jha SK. *Screening of Germplasms and Population Dynamics of Major Insect Pests of Spring Green Gram Vigna radiata (Linn.)* (Doctoral dissertation, Doctoral Dissertation, Doctoral Dissertation, GB Pant University of Agriculture and Technology, Pantnagar-263145 (Uttarakhand)).
21. Mehta V, Zargar AA, Attri P, Jha SK. Bagging the role of herbal drugs in the management of cervical cancer. Ayush Journal of Integrative Oncology. 2025 Jan 1;2(1):35-43.
22. Trivedi LM, Saxena S, Sharma S, Beniwal M, Jha SK, Rao AK, Khan MR. Characterization, profiling, and molecular docking analysis of phytochemicals derived from Daucus carota for evaluating their potential role in cardiovascular disease (CVD) assessment. World J Adv Res Rev. 2023;20:159-75.
23. Patel S, Singh S, Gupta AK, Dalimbe AY, Muthoju SM, Pawar AR, Jha SK, Gupta AJ. Ayurveda and common Indian spices: A natural alternative for cancer therapy. Ayush Journal of Integrative Oncology. 2025 Apr 1;2(2):91-102.
24. Jha SK, Gupta A, Huddar VG. Botanical breakthroughs: The growing impact of plant-derived compounds in cancer treatment. Ayush Journal of Integrative Oncology. 2025 Apr 1;2(2):62-7.
25. Kumar R, Verma H, Ali M, Midha T, Kumar D, Jha SK. Review of mitigating cancer risk through Ayurvedic practices: A holistic approach to combating sedentarism. Ayush Journal of Integrative Oncology. 2025 Apr 1;2(2):86-90.
26. Sharma A, Jha SK, Huddar VG. Integrative role of Ayurvedic phytochemicals in cancer treatment: Targeting signaling pathways, boosting chemosensitivity, and utilizing traditional therapeutics. Ayush Journal of Integrative Oncology. 2025 Apr 1;2(2):77-85.
27. Jha SK, Charde V, Kumar V, Narasimhaji CV. Vitiligo treatment with natural bioactive: A narrative review. The Natural Products Journal. 2026 Mar;16(3):e22103155337960.
28. Chawla S, Gupta R, Jha SK, Kashid S, Jha KT. Stereoisomerism in Chemistry and Drug Development: Optical, Geometrical, and

Conformational Isomers. Medicinal Chemistry (Shariqah (United Arab Emirates)). 2025.
29. Shrivastav S, Tyagi R, Singh M, Jha S. The effectiveness of curcumin on dysmenorrhea. International Journal of Medical Sciences and Pharma Research. 2022 Dec 15;8(4):8-12.
30. Gupta AJ, Huddar VG, Jha SK, Soni U. Traditional wisdom in modern oncology: Ayurvedic pain relief and supportive care. Ayush Journal of Integrative Oncology. 2025 Jul 1;2(3):178-87.
31. Chauhan S, Jha SK, Huddar VG, Ahlawat A, Sharma S, Tripathi A, Khurana B, Antil I, Soni U. Targeting cancer at the molecular level: A biochemical and medicinal chemistry approach. Ayush Journal of Integrative Oncology. 2025 Jul 1;2(3):169-77.
32. Antil I, Bangarwa S, Jha SK, Gupta AJ, Soni U, Huddar VG, Tripathi A, Sharma S. Exploring the chemopreventive and anticancer effects of green tea. Ayush Journal of Integrative Oncology. 2025 Jul 1;2(3):158-68.
33. Attri P, Zargar AA, Mehta V, Mushtaq SU, Jha SK, Soni U. Genetic basis of cancer: Harnessing natural remedies for therapeutic potential. Ayush Journal of Integrative Oncology. 2025 Jul 1;2(3):188-94.
34. Zargar AA, Mehta V, Gupta R, Bhandari K, Sharma MC, Balaji P, Jha SK. Incretin hormones: Mechanisms, therapeutic implications, and future directions in glucose regulation and diabetes management. Curr Proteom. 2025 Apr 1;22:100014.
35. Dhiman S, Thakur N, Dwivedi PC, Pande P, Jha SK, Lohiya GV. Phytochemicals: investigating bioactive compounds for antifungal uses and quality issues in functional foods and therapeutics.
36. Sandrepogu J, Khandelwal P, Tiwari SK, Jha SK, Chauhan S, Sharma H, Goel P. A holistic paradigm for cancer care: Merging Ayurveda with contemporary oncology. Ayush Journal of Integrative Oncology. 2025 Oct 1;2(4):254-61.
37. Sharma S, Yadav C, Chawla S, Jha SK. Beyond chemotherapy: Exploring the potential of phytomedicine in oncology. Ayush Journal of Integrative Oncology. 2025 Jul 1;2(3):133-45.
38. Ahlawat A, Chauhan S, Antil I, Jha SK, Huddar VG. Examining the impact of the microbiome on cancer immunotherapy outcomes: A review. Ayush Journal of Integrative Oncology. 2025 Jul 1;2(3):118-24.
39. Shamim PT, Khatri N, Yadav AK, Mishra B, Khan MR, Behera SK, Jha SK. Role of human chorionic gonadotropin in frozen-thawed embryo transfer cycles for secretory transformation: a narrative. Eur Chem Bull. 2023;12(8):5477-93.
40. Sharma H, Mahto RR, Jha SK, Chauhan S, Khandelwal P, Tiwari SK. Rasayana-Based Adjuvant Strategies in Cancer Care: An Ayurvedic–Oncologic Perspective. Iranian Journal of Blood and Cancer. 2025 Feb 30;17(4):35-68.
41. Raj H, Jha SK, Negi M, Khandelwal P, Chauhan S, Sharma H, Goel P, Tiwari SK. Integrative oncology: A comprehensive comparative analysis of herbal and allopathic medicine in cancer treatment. Current Pharmaceutical Research (CPR). 2025;1:427-5.
42. Kumar C, Chauhan P, Chauhan S, Jha SK, Lohiya G. Phyto-Pharmacognostic Experimental Study of Epimedium Sagittatum and Gloriosa Superba L. for the Treatment of Hypogonadism. Int J Innov Sci Res Technol. 2023;8(6):254-60.
43. Raj H, Sharma S, Tripathi A, Huddar VG, Jha SK. Herbal medicine in cancer therapy: A comprehensive review of phytoconstituents, mechanisms, and clinical applications. Ayush Journal of Integrative Oncology. 2025 Jul 1;2(3):146-57.
44. Antil I, Jha SK, Negi M, Sharma H, Tiwari SK. Baicalein from Scutellaria baicalensis as natural therapeutic agent for glioblastoma. Current Pharmaceutical Research (CPR). 2025;1:411-26.
45. Mandal P, Kumar J, Bora D, Hashmi SA, Tiwari M, Gupta R, Behera AK, Amoli M, Singh J, Jha SK. Literature review on forensic implications of illicit drug metabolism: A medicinal chemistry perspective. Journal of Forensic and Legal Medicine. 2026 Apr 24:103158.
46. Bansal KS, Mahto RR, Soni H, Tiwari SK, Goel P, Sharma H, Vishwakarma N, Jha SK, Chauhan S, Khandelwal P. Ayurveda in Renal Cell Carcinoma: A Narrative Review of Supportive Care During Targeted Therapy and Immunotherapy.
47. Mahto RR, Bansal KS, Soni H, Tiwari SK, Sandrepogu J, Bhatted SK, Jha SK, Sharma H, Khandelwal P. Efficacy of Vidangadi Loha and Phalatrikadi Ghanavati with and without the prior administration of Virechana Karma in Madhumeha (Obese Diabetic): A Randomised Controlled Trial.
48. Senapati S, Mahanta AK, Kumar S, Maiti P. Controlled drug delivery vehicles for cancer treatment and their performance. *Signal Transduct Target Ther.* 2018;3:7.
49. Parhi P, Mohanty C, Sahoo SK. Nanotechnology-based combinational drug delivery: an emerging approach for cancer therapy. *Drug Discov Today.* 2012;17(17–18):1044–1052.
50. He C, Liu D, Lin W. Nanomedicine applications in cancer therapy. *Bioconjug Chem.* 2015;26(6):1025–1036.
51. Shi Y, van der Meel R, Theek B, et al. Complete regression of xenograft tumors upon targeted delivery of paclitaxel via polymeric micelles. *ACS Nano.* 2015;9(4):3740–3752.
52. Mitchell MJ, Billingsley MM, Haley RM, et al. Engineering precision nanoparticles for drug delivery. *Nat Rev Drug Discov.* 2021;20(2):101–124.
53. Riley RS, Day ES. Gold nanoparticle-mediated photothermal therapy: applications and opportunities.

Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2017;9(4):e1449.
54. Wilhelm S, Tavares AJ, Dai Q, et al. Analysis of nanoparticle delivery to tumours. *Nat Rev Mater.* 2016;1:16014.
55. Sindhwani S, Syed AM, Ngai J, et al. The entry of nanoparticles into solid tumours. *Nat Mater.* 2020;19(5):566–575.
56. Bobo D, Robinson KJ, Islam J, et al. Nanoparticle-based medicines: a review of FDA-approved materials. *Pharm Res.* 2016;33(10):2373–2387.
57. Anselmo AC, Mitragotri S. Nanoparticles in the clinic: an update. *Bioeng Transl Med.* 2019;4(3):e10143.
58. Kulkarni JA, Cullis PR, van der Meel R. Lipid nanoparticles enabling gene therapies. *Nat Rev Drug Discov.* 2018;17(9):613–614.
59. Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. *Nat Rev Mater.* 2021;6:1078–1094.
60. Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. *Nat Rev Cancer.* 2013;13(10):714–726.
61. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. *Nat Nanotechnol.* 2007;2(12):751–760.